Ligand Pharmaceuticals delivered exceptional financial performance with revenue surging 323% to $141.1M and swinging from a $4.0M loss to $124.5M profit, while simultaneously dramatically expanding its balance sheet with total assets growing 66% to $1.6B.
This represents a transformational year for LGND, suggesting major deal closures, milestone payments, or strategic acquisitions that fundamentally altered the company's scale and profitability. The massive increase in total liabilities to $543.4M alongside asset growth indicates significant new obligations or debt, requiring careful analysis of the underlying transactions driving these changes.
LGND experienced explosive growth across virtually all financial metrics, with revenue jumping over 300% and the company swinging decisively to profitability despite R&D spending nearly tripling to $81.2M. The balance sheet expanded dramatically with total assets reaching $1.6B and cash more than doubling to $174.9M, though total liabilities surged nearly 400% to $543.4M. This financial transformation suggests major strategic transactions or partnership deals that have fundamentally repositioned the company, though the massive liability increase warrants scrutiny of the underlying deal structures and future obligations.
Net income grew 3186.6% — bottom-line growth signals improving overall business health.
Liabilities grew 388.1% — significant increase in debt or obligations, assess impact on financial flexibility.
Strong top-line growth of 322.8% — accelerating demand or successful expansion into new markets.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
R&D investment increased 278.9% — signals commitment to future product development, though near-term margin impact.
Current assets grew 151% — improving short-term liquidity or inventory/receivables build.
Cash position surged 141.9% — strong cash generation or capital raise providing significant financial cushion.
Capex reduced 75.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Asset base grew 65.7% — expansion through organic growth, acquisitions, or capital deployment.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →